Twice-Yearly PrEP Is Here: What You Need to Know About the New HIV Prevention Shot
Living with HIV means committing to a daily routine. For millions of people around the world, that routine includes taking antiretroviral therapy (ART) every single day — without exception. One missed dose can mean a drop in viral suppression. Two missed doses can lead to resistance. The pressure is constant. The pills are always there. And over time, that weight becomes exhausting. It's called pill fatigue — and it's one of the most common challenges people living with HIV face.But what if there was another way? What if you could maintain complete viral suppression without a daily pill?In recent years, long-acting injectable HIV treatments have emerged as a game-changing alternative. These are not experimental therapies — they are FDA-approved, clinically proven, and available today. Instead of taking a pill every morning, you receive a single injection every one to two months. That's it. No daily reminder. No pharmacy trips every few weeks. No fear of missing a dose.
For years, daily oral PrEP has been the standard approach for HIV prevention among people at higher risk. While effective, the requirement to take a pill every single day has been a barrier for many. A new long-acting injectable option is now available that requires only two doses per year, offering a practical alternative for those who prefer a less frequent routine.
What Is the New PrEP Injection?
The new PrEP injection every 6 months uses the drug lenacapavir, developed by Gilead Sciences under the brand name Yeztugo. The FDA approved Yeztugo in June 2025 for HIV prevention in adults and adolescents who are at risk for HIV but do not currently have the virus. It works as a capsid inhibitor, blocking the HIV virus from replicating inside the body. Clinical trial data showed a remarkably high rate of protection, with near-complete prevention of HIV infection among trial participants, making it one of the most effective prevention tools studied to date.
How Does Long-Acting PrEP Work?
Understanding how long-acting PrEP works helps explain why it is such a significant development. Lenacapavir is injected subcutaneously, typically in the abdomen, and slowly releases into the body over approximately six months. This sustained release keeps drug levels consistently high enough to block HIV from establishing an infection, even in the event of exposure. Unlike daily pills, which depend on consistent adherence, the injection maintains protective levels without the need for daily action by the person receiving it.
Yeztugo FDA Approval and What It Means
The Yeztugo FDA approval represents a major regulatory milestone. It was evaluated under the FDA’s Priority Review pathway, given the public health significance of HIV prevention. The approval covers its use in HIV-negative individuals at risk for sexually acquired HIV. Healthcare providers can now prescribe it as a standalone PrEP option, giving patients and doctors more flexibility in choosing the approach that fits an individual’s lifestyle, health history, and preferences.
Who Can Benefit From the Twice-Yearly HIV Prevention Shot?
The twice-yearly HIV prevention shot is particularly relevant for people who have difficulty adhering to a daily pill regimen, whether due to busy schedules, privacy concerns, stigma, or other personal factors. It may also be a strong option for people who have experienced side effects from oral PrEP medications. Healthcare providers will typically conduct standard screenings before prescribing, including HIV testing and kidney function assessments, to determine whether this option is appropriate.
Cost and Access Considerations for New PrEP Injection 2026
Cost is a practical concern for many people considering PrEP in the United States. As of the time of writing, lenacapavir (Yeztugo) is a newer medication and its pricing reflects that. The table below provides a general overview of PrEP-related cost estimates across different options for comparison purposes.
| Product/Service | Provider | Cost Estimation |
|---|---|---|
| Yeztugo (lenacapavir injection) | Gilead Sciences | Estimated $40,000+ per year without insurance |
| Truvada (daily oral PrEP) | Gilead Sciences | Approximately $2,000/month without coverage |
| Generic emtricitabine/tenofovir | Various generic manufacturers | Approximately $30–$60/month with assistance programs |
| Descovy (oral PrEP) | Gilead Sciences | Approximately $2,000/month without coverage |
| Apretude (cabotegravir injection, 2x/year) | ViiV Healthcare | Estimated $22,000+ per year without insurance |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
For many people in the United States, insurance coverage, Medicaid, and patient assistance programs from manufacturers can significantly reduce out-of-pocket costs. The Affordable Care Act requires most private insurance plans to cover FDA-approved PrEP without cost-sharing. Community health centers and sexual health clinics often provide guidance on accessing these programs.
Talking to a Healthcare Provider
Anyone interested in the new PrEP injection should speak with a qualified healthcare provider who can assess personal risk factors, review current medications for potential interactions, and explain the full process of starting and maintaining this prevention method. Regular follow-up visits are part of the injectable PrEP process to monitor health and confirm continued HIV-negative status.
The arrival of a twice-yearly injectable PrEP option expands the toolkit available for HIV prevention in a meaningful way. With strong clinical evidence behind it and FDA approval in place, it represents a practical and powerful option for many people seeking protection from HIV on their own terms.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
